Pharmaceutics (Sep 2022)

NIL10: A New IL10-Receptor Binding Nanoparticle That Induces Cardiac Protection in Mice and Pigs Subjected to Acute Myocardial Infarction through STAT3/NF-κB Activation

  • Laura Tesoro,
  • Ignacio Hernández,
  • Rafael Ramírez-Carracedo,
  • Javier Díez-Mata,
  • Nunzio Alcharani,
  • Beatriz Jiménez-Guirado,
  • Karina Ovejero-Paredes,
  • Marco Filice,
  • Jose Luis Zamorano,
  • Marta Saura,
  • Carlos Zaragoza,
  • Laura Botana

DOI
https://doi.org/10.3390/pharmaceutics14102044
Journal volume & issue
Vol. 14, no. 10
p. 2044

Abstract

Read online

(1) Background: Early response after acute myocardial infarction (AMI) prevents extensive cardiac necrosis, in which inflammation resolution, including expression of anti-inflammatory interleukin-10 (IL-10), may play a key role. (2) Methods: We synthesized NIL10, a micelle-based nanoparticle, to target IL-10 receptor in mice and pigs subjected to AMI. (3) Results: Administration of NIL10 induced cardiac protection of wild-type and IL-10 knockout mice and pigs subjected to AMI. Cardiac protection was not induced in IL-10-receptor null mice, as shown by a significant recovery of cardiac function, in which inflammatory foci and fibrosis were strongly reduced, together with the finding that resolving M2-like macrophage populations were increased after day 3 of reperfusion. In addition, anti-inflammatory cytokines, including IL-4, IL-7, IL-10, IL-13, IL-16, and IL-27 were also elevated. Mechanistically, NIL10 induced activation of the IL-10 receptor/STAT-3 signaling pathway, and STAT3-dependent inhibition of nuclear translocation of pro-inflammatory NF-ĸB transcription factor. (4) Conclusions: Taken together, we propose using NIL10 as a novel therapeutic tool against AMI-induced cardiac damage.

Keywords